Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATMOS phase 2 study of galvokimig in adults with non-cystic fibrosis bronchiectasis
jRCT2031260579Phase 2Not yet recruiting
- Sponsor
- UCB
- Start
- Nov 2026
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis comparing Galvokimig with Placebo (2 arms). Primary endpoint: Time from intervention assignment to first moderate or severe pulmonary exacerbation. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
galvokimig
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on jRCT2031260579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260579.